Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.
Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, Fennelly KP, Te Riele J, Mastrapa B, Streicher EM, Dolby T, Abdallah AM, Ben-Rached F, Simpson J, Smith L, Gumbo T, van Helden P, Sirgel FA, McNerney R, Theron G, Pain A, Clark TG, Warren RM. Dheda K, et al. Among authors: te riele j. Lancet Respir Med. 2017 Apr;5(4):269-281. doi: 10.1016/S2213-2600(16)30433-7. Epub 2017 Jan 19. Lancet Respir Med. 2017. PMID: 28109869 Free article.
High frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosis.
Pietersen E, Peter J, Streicher E, Sirgel F, Rockwood N, Mastrapa B, Te Riele J, Davids M, van Helden P, Warren R, Dheda K. Pietersen E, et al. Among authors: te riele j. PLoS One. 2015 Apr 24;10(4):e0123655. doi: 10.1371/journal.pone.0123655. eCollection 2015. PLoS One. 2015. PMID: 25909847 Free PMC article.
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, Padanilam X, Enwerem M, Chotoo S, Singh N, Hughes J, Variava E, Ferreira H, Te Riele J, Ismail N, Mohr E, Bantubani N, Conradie F. Ndjeka N, et al. Among authors: te riele j. Eur Respir J. 2018 Dec 20;52(6):1801528. doi: 10.1183/13993003.01528-2018. Print 2018 Dec. Eur Respir J. 2018. PMID: 30361246 Free article.
Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?
Ndjeka N, Conradie F, Meintjes G, Reuter A, Hughes J, Padanilam X, Ismail N, Kock Y, Master I, Romero R, Te Riele J, Enwerem M, Ferreira H, Maartens G. Ndjeka N, et al. Among authors: te riele j. Eur Respir J. 2020 Jul 23;56(1):2001369. doi: 10.1183/13993003.01369-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32471936 Free PMC article.
Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis.
Theron G, Limberis J, Venter R, Smith L, Pietersen E, Esmail A, Calligaro G, Te Riele J, de Kock M, van Helden P, Gumbo T, Clark TG, Fennelly K, Warren R, Dheda K. Theron G, et al. Among authors: te riele j. Nat Med. 2020 Sep;26(9):1435-1443. doi: 10.1038/s41591-020-0940-2. Epub 2020 Jun 29. Nat Med. 2020. PMID: 32601338 Free PMC article.
Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
Brust JCM, Gandhi NR, Wasserman S, Maartens G, Omar SV, Ismail NA, Campbell A, Joseph L, Hahn A, Allana S, Hernandez-Romieu AC, Zhang C, Mlisana K, Viljoen CA, Zalta B, Ebrahim I, Franczek M, Master I, Ramangoaela L, Te Riele J, Meintjes G. Brust JCM, et al. Among authors: te riele j. Clin Infect Dis. 2021 Dec 6;73(11):2083-2092. doi: 10.1093/cid/ciab335. Clin Infect Dis. 2021. PMID: 33882121 Free PMC article.
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
Ismail NA, Omar SV, Moultrie H, Bhyat Z, Conradie F, Enwerem M, Ferreira H, Hughes J, Joseph L, Kock Y, Letsaolo V, Maartens G, Meintjes G, Ngcamu D, Okozi N, Padanilam X, Reuter A, Romero R, Schaaf S, Te Riele J, Variava E, van der Meulen M, Ismail F, Ndjeka N. Ismail NA, et al. Among authors: te riele j. Lancet Infect Dis. 2022 Apr;22(4):496-506. doi: 10.1016/S1473-3099(21)00470-9. Epub 2021 Nov 12. Lancet Infect Dis. 2022. PMID: 34780706
20 results